# Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

> **NCT00450385** · PHASE2 · TERMINATED · sponsor: **University of Miami** · enrollment: 57 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00450385
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04-24
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Investigator Decision due to insufficient accrual.
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450385, "Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00450385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*